680C91

680C91 is an orally active, selective tryptophan 2,3-dioxygenase (TDO) inhibitor with a Ki of 51 nM. TDO is the key enzyme of tryptophan catabolism. 680C91 can be used for the research of cancer immunotherapy and Alzheimer’s Disease[1][2][3][4].

Product Specifications

CAS Number

[163239-22-3]

UNSPSC

12352005

Hazard Statement

H318

Target

Collagen

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/680c91.html

Purity

99.54

Solubility

DMSO : 116.67 mg/mL (ultrasonic)

Smiles

FC1=CC2=C(C=C1)C(/C=C/C3=CC=CN=C3)=CN2

Molecular Formula

C15H11FN2

Molecular Weight

238.26

Precautions

H318

References & Citations

[1]M Salter, et al. The effects of an inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3-dioxygenase and 5-HT reuptake in the rat. Neuropharmacology. 1995 Feb;34 (2) :217-27.|[2]M Salter, et al. The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. Biochem Pharmacol. 1995 May 17;49 (10) :1435-42.|[3]Dang-Dang Li, et al. Differential expression and regulation of Tdo2 during mouse decidualization. J Endocrinol. 2013 Dec 2;220 (1) :73-83.|[4]Tsai-Der Chuang, et al. Tryptophan catabolism is dysregulated in leiomyomas. Fertil Steril. 2021 Oct;116 (4) :1160-1171.|[5]Sophie Imbeault, et al. Effects of IDO1 and TDO2 inhibition on cognitive deficits and anxiety following LPS-induced neuroinflammation. Acta Neuropsychiatr. 2020 Feb;32 (1) :43-53.|[6]Li DD, et al. Differential expression and regulation of Tdo2 during mouse decidualization. J Endocrinol. 2013 Dec 2;220 (1) :73-83.